Clin Osteol 2004; 9(1): 18-21

Profile of patients presenting with postmenopausal osteoporosis treated with raloxifeneArticles

J. Rosa, P. Vaňuga, M. Noskovič, A. Ritomský

Appropriate patient's compliance is a pre-requisite for effective long-term treatment of osteoporosis. Compliance data from randomized clinical trials generally do not provide reliable compliance-related information in clinical practice. CORAL (COmpliance with RALoxifene Therapy) is a local Slo­ vak prospective multicentric observational study. Primary goal is to evaluate compliance with raloxifene treatment in clinical practice conditions. Se­ condary goals include quality of life, safety and proportion of patients at increased cardiovascular risk assessments. The 18-months observation inclu­ des 1 517 patients by study start with diagnosed postmenopausal osteoporosis enrolled in 40 sites. Baseline patient's data are presented in here. The scoring system developed for enrolment of patients into the RUTH (Raloxifene Use for The Hear risk score. In selected centers quality of life was assessed using EuroQoL (EQ-5D) questionnaire. Baseline data in 1 350 patients were evaluated. Mean patients age is 63,2 ± 8,0 years. In patients enrolled on basis of low bone mineral density osteo­ porosis of the lumbar spine was detected in 69,1 % of patients, osteoporosis of the proximal femur in 28,7 % of patients. In 23,2 % of cases osteoporosis was detected at both sites. 27,1 % of patients sustained fracture past 50 years of age. The mean cardiovascular risk score was 2,03 (±1,97). Cardiovascu­ lar risk score > 4 (increa inflammatory drugs regularly. The CORAL study represents first project of its kind exploring an antiresorptive drug of osteoporosi of the Slovak Republic.

Keywords: osteoporóza, raloxifen, observační studie, compliance.

Published: June 11, 2004  Show citation